一分钟看懂
这是一项关于Advanced or Metastatic Pancreatic Adenocarcinoma的II 期研究，登记的药物或干预包括Trastuzumab emtansine (T-DM1)；Trastuzumab deruxtecan (T-DXd)；Datopotamab deruxtecan (Dato-DXd)；Sacituzumab govitecan (SG)；Enfortumab vedotin，当前状态为尚未开始招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Trastuzumab emtansine (T-DM1)；Trastuzumab deruxtecan (T-DXd)；Datopotamab deruxtecan (Dato-DXd)；Sacituzumab govitecan (SG)；Enfortumab vedotin (EV)；Becotatug vedotin (MRG003)；Izalontamab brengitecan (iza-bren / BL-B01D1)；Mirvetuximab soravtansine (MIRV) · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Cancer · 上海
公开的入选条件
- 1. Male or female patients aged ≥18 years and ≤75 years at the time of informed consent.
- 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- 3. Life expectancy of ≥3 months, as assessed by the investigator.
- 4. Histologically confirmed recurrent (unresectable) or metastatic advanced pancreatic cancer or breast cancer.
- 5. Radiographic or objective evidence of disease progression during or following the last systemic therapy administered prior to the first dose of study treatment.
- 6. Documented failure of standard-of-care therapy in the recurrent/metastatic setting, with receipt of at least 2 prior lines of chemotherapy. If disease recurrence occurs within 6 months after completion of (neo)adjuvant chemotherapy, the adjuvant chemotherap
- For patients with hormone receptor-positive (estrogen receptor \[ER\]-positive and/or progesterone receptor \[PR\]-positive) and HER2-negative tumors: progression after at least 1 line of endocrine therapy, with the investigator's determination that the patien
- For patients with HER2-positive advanced breast cancer: receipt of at least 2 prior lines of anti-HER2 therapy.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07825753；登记信息更新于 2026-09-17。